表紙
市場調査レポート

CymaBay Therapeutics, Inc.:製品パイプライン分析

CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 333713
出版日 ページ情報 英文 29 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
CymaBay Therapeutics, Inc.:製品パイプライン分析 CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年05月27日 ページ情報: 英文 29 Pages
概要

当レポートでは、CymaBay Therapeutics, Inc.における医薬品の研究開発 (R&D) 動向について分析し、開発活動の全体的な進行状況や、開発段階 (相/フェーズ) 別のパイプライン製品情報、標的・作用機序 (MoA)・投与経路 (RoA)・分子タイプ別の詳細動向、昨今の主な動き (プレスリリース他)、最終段階/中断されたプロジェクトの概略といった情報を取りまとめてお届けいたします。

目次

  • CymaBay Therapeutics, Inc.:最新動向
    • 概要
    • 主要情報
    • 主要データ
  • CymaBay Therapeutics, Inc.:研究開発 (R&D) の概要
    • 主な治療領域
  • CymaBay Therapeutics, Inc.:パイプライン分析
    • パイプライン製品:開発段階別
    • パイプライン製品:単剤療法
    • パイプライン製品:アウトライセンス製品
      • アウトライセンス製品/併用療法のモダリティ
  • CymaBay Therapeutics, Inc.:パイプライン製品の概略
    • 治験段階別のパイプライン製品
      • 第II相製品/併用療法のモダリティ
      • 第I相製品/併用療法のモダリティ
  • CymaBay Therapeutics, Inc.:薬剤のプロファイル
    • arhalofenate
      • 製品概略
      • 作用機序
      • 研究開発 (R&D) の進展
    • MBX-2982
    • MBX-8025
  • CymaBay Therapeutics, Inc.:パイプライン分析
    • パイプライン製品:標的別
    • パイプライン製品:投与経路別
    • パイプライン製品:分子の種類別
    • パイプライン製品:作用機序別
  • CymaBay Therapeutics, Inc.:パイプライン製品の最新動向
  • CymaBay Therapeutics, Inc.:休止状態のプロジェクト
  • CymaBay Therapeutics, Inc.:事業拠点・関連企業
    • 本社
  • 付録

図表一覧

目次
Product Code: GMDHC07137CDB

Summary

Global Markets Direct's, 'CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the CymaBay Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CymaBay Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CymaBay Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CymaBay Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CymaBay Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate CymaBay Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CymaBay Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CymaBay Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CymaBay Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CymaBay Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CymaBay Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CymaBay Therapeutics, Inc. Snapshot
    • CymaBay Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • CymaBay Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CymaBay Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • CymaBay Therapeutics, Inc. - Pipeline Products Glance
    • CymaBay Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • CymaBay Therapeutics, Inc. - Drug Profiles
    • arhalofenate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2982
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CymaBay Therapeutics, Inc. - Pipeline Analysis
    • CymaBay Therapeutics, Inc. - Pipeline Products by Target
    • CymaBay Therapeutics, Inc. - Pipeline Products by Route of Administration
    • CymaBay Therapeutics, Inc. - Pipeline Products by Molecule Type
    • CymaBay Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • CymaBay Therapeutics, Inc. - Recent Pipeline Updates
  • CymaBay Therapeutics, Inc. - Dormant Projects
  • CymaBay Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CymaBay Therapeutics, Inc., Key Information
  • CymaBay Therapeutics, Inc., Key Facts
  • CymaBay Therapeutics, Inc. - Pipeline by Indication, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • CymaBay Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • CymaBay Therapeutics, Inc. - Phase II, 2015
  • CymaBay Therapeutics, Inc. - Phase I, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Target, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • CymaBay Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CymaBay Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • CymaBay Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • CymaBay Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • CymaBay Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top